Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

ATJMED. 2022; 2(1): 16-9


Membranous glomerulonephritis with positive serum PLA2R antibodies: A case report of replacing membranous nephropathy, massive proteinuria despite immunosuppressive therapies

Ceren Cicek, Gozde Nur Sari.




Abstract

Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in non-diabetic adults, accounting for up to one-third of biopsied cases of nephrotic syndrome.

The term MN reflects the primary histologic change noted on light microscopy: glomerular basement membrane (GBM) thickening with little or no cellular proliferation or infiltration MN is most often primary (previously called idiopathic), although it has been associated with hepatitis B antigene, autoimmune diseases, thyroiditis, malignancies (1,2).

This case has been reported as its rarely encountered in our clinical practice. Its progression is worsened despite immunosuppressive treatment. The case of male patients with primary membranous nephropathy is presented. He was three years. Still, the nephrosis recurred with massive proteinuria (19180 mg/day) in treated corticosteroid and cyclosporine after conservative therapy had failed and went into remission for addition to weight loss without .

Key words: Membranous Glomerulonephritis, Therapies, Prognosis, Malignancy, Positive serum PLA2R antibodies






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.